English
Supriya Lifescience Q2 Results
- BSE: 543434
- NSE: SUPRIYA
- ISIN: INE07RO01027
- Sector: Biotechnology & Drugs
BSE
714.45
-34.60 (-4.62%)
-34.60 (-4.62%)Volume6.56 K
Updated: Fri 23 Jan, 2026 | 15:28:00
NSE
716.05-31.25 (-4.18%)
-31.25 (-4.18%)Volume1.13 L
Updated: Fri 23 Jan, 2026 | 15:40:15
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹199.83 Cr.(20.31%)
- Operating Profit₹66.01 Cr.(10.06%)
- Profit After Tax₹50.43 Cr.(9.27%)
- Operating Margin33.03%(-8.52%)
Note: Comparison is on YoY basis
Quarterly - Supriya Lifescience Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 133.83 | 99.82 | 34.06% | 106.13 | 26.10% |
| Depreciation/ Amortization | 6.64 | 6.45 | 2.91% | 4.74 | 39.95% |
| Operating Income | 66.01 | 45.25 | 45.87% | 59.97 | 10.06% |
| Net Income | 50.43 | 34.79 | 44.95% | 46.15 | 9.27% |
| Other Operating Expenses Total | 46.98 | 38.91 | 20.72% | 35.73 | 31.49% |
| Net Income Before Taxes | 68.32 | 47.41 | 44.09% | 62.06 | 10.08% |
| Total Revenue | 199.83 | 145.07 | 37.75% | 166.10 | 20.31% |
| Selling/ General/ Admin Expenses Total | 24.48 | 22.69 | 7.90% | 19.69 | 24.36% |
| Diluted Normalized EPS | 6.27 | 4.32 | 45.14% | 5.71 | 9.81% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.